drugset / Trial / NCT00368030

A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder

NCT00368030

Phase 3 Completed 545 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate subjective sleep efficacy in subjects with insomnia related to major depressive disorder.

Timeline

Start
2004-01
Primary completion
2004-10
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Eszopiclone Small molecule 3 mg